Complementary Healthcare Analysis - 2019-09-24
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
| Top Gainers | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Avadel Pharmaceuticals plc (AVDL) | 164.50M | 4.47 | 32.64% | 11,473,092 | |
| OPKO Health, Inc. (OPK) | 1.33B | 2.13 | 5.45% | 2,976,808 | |
| BioCryst Pharmaceuticals, Inc. (BCRX) | 361.73M | 3.23 | 12.94% | 2,531,994 | |
| Melinta Therapeutics, Inc. (MLNT) | 50.69M | 3.82 | 22.44% | 1,557,126 | |
| Puma Biotechnology, Inc. (PBYI) | 478.31M | 11.91 | 10.07% | 1,473,488 | |
| Top Losers | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 563.23M | 5.51 | -16.77% | 8,389,755 | |
| Plus Therapeutics, Inc. (PSTV) | 1.86M | 4.05 | -49.50% | 6,930,639 | |
| Endo International plc (ENDP) | 712.60M | 3.26 | -6.32% | 6,130,885 | |
| Iovance Biotherapeutics, Inc. (IOVA) | 2.44B | 19.75 | -5.68% | 3,046,697 | |
| Abeona Therapeutics Inc. (ABEO) | 140.69M | 2.87 | -11.96% | 2,251,914 | |
| High volume stocks reaching new highs | |||||
| Company | Market Cap | Price | Change% | Volume | |
| DURECT Corporation (DRRX) | 376.63M | 2.21 | 3.27% | 3,178,467 | |
| Celgene Corporation (CELG) | 70.26B | 99.42 | 0.05% | 3,128,528 | |
| The Medicines Company (MDCO) | 3.72B | 47.75 | -2.77% | 1,385,955 | |
| High volume stocks reaching new lows | |||||
| Company | Market Cap | Price | Change% | Volume | |
| Plus Therapeutics, Inc. (PSTV) | 1.86M | 4.05 | -49.50% | 6,930,639 | |
| Sienna Biopharmaceuticals, Inc. (SNNA) | 4.72M | 0.15 | -9.03% | 3,826,571 | |
| Clovis Oncology, Inc. (CLVS) | 257.49M | 4.59 | -3.27% | 3,366,295 | |
| Sundial Growers Inc. (SNDL) | 668.66M | 6.70 | -5.23% | 1,155,533 | |
| Sarepta Therapeutics, Inc. (SRPT) | 6.18B | 80.38 | -2.58% | 1,023,506 | |
| Major Analyst Upgrades | |||||
| Company | Current Rating | New Rating | Analyst | Current Price | Target Price |
| Mirati Therapeutics (MRTX) | Neutral | Buy | Guggenheim | $93.60 | $116.00 |
| Major Analyst Downgrades | |||||
| Company | Current Rating | New Rating | Analyst | Current Price | Target Price |
| Clovis Oncology (CLVS) | Outperform | Market Perform | Leerink Swann | $4.16 | |
| Outperform | Market Perform | Svb Leerink | $4.16 | $10.00 | |
| Major Insider Buys | |||||
| Company | Insider Name | Insider Title | Price | Qty | Value |
| Athenex, Inc. (ATNX) | Lau Johnson Yiu Nam | CEO, COB, 10% | $13.86 | 5000 | +$69,300 |
| Cymabay Therapeutics, Inc. (CBAY) | Shah Sujal | CEO | $5.53 | 5000 | +$27,655 |
| Igm Biosciences, Inc. (IGMS) | Topsoe Jakob Haldor | Dir, 10% | $22.01 | 14340 | +$315,610 |
| Topsoe Jakob Haldor | Dir, 10% | $19.54 | 1700 | +$33,212 | |
| Soligenix, Inc. (SNGX) | Parks Diane L. | Dir | $0.93 | 14940 | +$13,870 |
| Zeldis Jerome B | Dir | $0.94 | 4000 | +$3,740 | |
| Major Insider Sells | |||||
| Company | Insider Name | Insider Title | Price | Qty | Value |
| Adamas Pharmaceuticals Inc (ADMS) | Merriweather Alfred G | CFO | $6.91 | -1584 | -$10,945 |
| Alkermes Plc. (ALKS) | Pops Richard F | Dir, CEO, Alkermes plc | $21.54 | -100000 | -$2,153,550 |
| Chiasma, Inc (CHMA) | Mamluk Roni | Dir | $5.59 | -50000 | -$279,500 |
| Deciphera Pharmaceuticals, Inc. (DCPH) | Martin Daniel C. | Chief Commercial Officer | $35.56 | -3000 | -$106,688 |
| Fibrogen Inc (FGEN) | Chung Christine | SVP, China Operations | $40.16 | -11250 | -$451,819 |
| Gossamer Bio, Inc. (GOSS) | Omega Fund V, L.P. | 10% | $21.96 | -183607 | -$4,032,561 |
| Lilly Eli & Co (LLY) | Lilly Endowment Inc | 10% | $116.37 | -210000 | -$24,437,726 |
| Zulueta Alfonso G | SVP, Pres, Lilly Int'l | $117.00 | -4500 | -$526,500 | |
| Tyme Technologies, Inc. (TYME) | Demurjian Michael | 10% | $1.67 | -20000 | -$33,436 |
Index Watch
NASDAQ Health Care
INDEXNASDAQ: IXHC
iShares NASDAQ Biotechnology Index
NASDAQ: IBB
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.